معرفی
Edouard Zamaratski serves as a Researcher in the Department of Medicinal Chemistry at Uppsala University, Sweden, where he contributes to the Drug Design and Discovery research group. His academic role centers on advancing antibacterial drug discovery through interdisciplinary collaboration between synthetic chemistry and microbiology.
His research program focuses on:
- Developing novel inhibitors targeting lipopolysaccharide synthesis (LpxH) in Gram-negative pathogens
- Designing sulfonimidamide-based oligopeptides as type I signal peptidase inhibitors
- Creating innovative synthetic methodologies for antibiotic scaffolds
- Evaluating compound efficacy through rigorous in vitro and in vivo models
Analysis of his publication trajectory (2017-2024) reveals a strategic evolution from foundational synthetic chemistry to advanced biological validation. A dominant trend is the rational targeting of underexplored bacterial enzymes with chemically diverse scaffolds, yielding multiple antibiotic classes with activity against drug-resistant Gram-negative infections.
Dr. Zamaratski actively participates in Uppsala's Drug Design and Discovery ecosystem, collaborating with microbiologists and pharmacologists to translate chemical innovations into therapeutic candidates addressing the antimicrobial resistance crisis.
